GLP-1 Weight Loss
Mino GLP3-RT
Retatrutide — active ingredient
Compounded Retatrutide · Triple-agonist class
Triple GIP/GLP-1/glucagon agonist representing the next generation of weight-loss therapy.
Overview
Retatrutide is a next-generation triple agonist that activates GIP, GLP-1, and glucagon receptors simultaneously. By adding glucagon-receptor activity to the dual-pathway approach, it has shown some of the largest weight-loss results reported in clinical research to date.
At Mino MD, retatrutide (Mino GLP3-RT) is prescribed only after a licensed physician reviews your health history, BMI, and lab markers, and is dispensed through a U.S. compounding pharmacy with a careful titration plan.
How it works
Retatrutide engages three complementary metabolic pathways: GLP-1 and GIP reduce appetite and improve insulin response, while glucagon-receptor activity increases energy expenditure. Together they can drive significant appetite suppression and fat loss.
Benefits
- Triple-pathway action on appetite, blood sugar, and energy expenditure
- Among the most powerful weight-loss results seen in clinical trials
- Once-weekly subcutaneous injection
- May benefit patients seeking results beyond dual-agonist therapy
- Conservative titration to support tolerability
Dosing
Retatrutide is dosed once weekly with a gradual titration that your physician personalizes based on your response and tolerability. Because it is a newer, potent therapy, Mino MD uses an especially measured ramp.
Who it's for
Considered for adults with a BMI of 30+ , or 27+ with a weight-related condition, who are appropriate candidates for advanced GLP-1 therapy. The same guided H&P and AI contraindication review apply, ruling out medullary thyroid carcinoma, MEN2, pregnancy, and other contraindications.
Possible side effects
- Nausea or decreased appetite, especially during titration
- Diarrhea or constipation
- Increased heart rate in some patients
- As a newer therapy, long-term data continue to develop
Frequently asked questions
How is retatrutide different from semaglutide and tirzepatide?
Semaglutide targets one receptor (GLP-1) and tirzepatide targets two (GIP and GLP-1). Retatrutide adds a third — the glucagon receptor — which may increase energy expenditure and produce greater weight loss for some patients. Your physician will recommend the right option for you.
Is retatrutide FDA approved?
Retatrutide is still investigational and not yet FDA approved as a finished brand drug. Mino MD offers it as a compounded therapy under physician supervision; your provider will review the current evidence and risks with you.
How is retatrutide taken?
It is a once-weekly subcutaneous injection. You follow the titration schedule your physician sets and rotate injection sites.
Who is a good candidate for Mino GLP3-RT?
It may suit adults seeking advanced weight-loss results, including those who have plateaued on other GLP-1 therapies. Eligibility is confirmed through the Mino MD guided H&P and contraindication screen.